Trial Outcomes & Findings for Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia (NCT NCT00804856)

Last Updated: 2023-10-03

Results Overview

To determine the Maximum tolerated dose (MTD), dose escalation was conducted following the 3+3 design with de-escalation. The MTD was defined as the highest dose at which 6 patients had been treated and less than 2 patients experienced a Dose limiting toxicity (DLT) within the first cycle of treatment. The MTD was defined based on safety data from the first cycle only. DLT is defined as drug related Common terminology criteria for adverse events (CTCAE) grade ≥ 3 nonhaematological toxicity (excluding: untreated nausea, untreated vomiting, CTCAE grade 3 untreated diarrhoea, CTCAE grade 3 "febrile neutropenia" and CTCAE grade 3 "infection with grade 3 or 4 neutrophils"). In patients with complete remission with incomplete blood count recovery (CRi) or partial remission (PR), persistent CTCAE grade 4 neutropenia or thrombocytopenia until three weeks after the end of the treatment cycle will be regarded a DLT.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

180 participants

Primary outcome timeframe

First Treatment cycle, up to 28 days.

Results posted on

2023-10-03

Participant Flow

Open-label, randomized, dose escalation study. In this trial 180 patients were entered and randomised. However 3 patients were entered but not treated in Phase I and 2 patients were not treated in Phase II. Thus total 175 patients were treated in this trial.

Patients were assigned to two treatment schedules (A and B) in the phase I part of the trial (dose escalation phase to determine maximum tolerated dose (MTD)). In the phase IIa part of the trial (after MTD was determined), patients were randomised to two treatment schedules (A and C).

Participant milestones

Participant milestones
Measure	Phase I Schedule A. Volasertib 150 mg+LDAC Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 200 mg+LDAC Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 250 mg+LDAC Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 300 mg+LDAC Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 400 mg+LDAC Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule B. Volasertib 150 mg Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 200 mg Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 350 mg Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 400 mg Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 450 mg Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 500 mg Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 550 mg Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase II Schedule C. LDAC Low-dose cytarabine (LDAC) monotherapy 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Phase II Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) on Days 1 and 15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.
Overall Study STARTED	4	3	5	9	8	3	11	2	5	6	23	5	4	45	42
Overall Study COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Overall Study NOT COMPLETED	4	3	5	9	8	3	11	2	5	6	23	5	4	45	42

Reasons for withdrawal

Reasons for withdrawal
Measure	Phase I Schedule A. Volasertib 150 mg+LDAC Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 200 mg+LDAC Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 250 mg+LDAC Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 300 mg+LDAC Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 400 mg+LDAC Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule B. Volasertib 150 mg Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 200 mg Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 350 mg Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 400 mg Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 450 mg Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 500 mg Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 550 mg Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase II Schedule C. LDAC Low-dose cytarabine (LDAC) monotherapy 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Phase II Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) on Days 1 and 15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.
Overall Study Progressive Disease	3	2	4	6	4	1	8	2	4	5	12	2	2	26	20
Overall Study Dose Limiting Toxicity (DLT)	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1
Overall Study Other Adverse Event	1	1	1	2	2	1	3	0	0	1	5	2	0	6	13
Overall Study Non compliance with protocol	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0
Overall Study Refused to continue medication	0	0	0	1	1	0	0	0	0	0	3	0	1	1	5
Overall Study Other reason than listed above	0	0	0	0	0	1	0	0	1	0	3	1	1	10	3

Baseline Characteristics

Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Phase I Schedule A. Volasertib 150 mg+LDAC n=4 Participants Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 200 mg+LDAC n=3 Participants Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 250 mg+LDAC n=5 Participants Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 300 mg+LDAC n=9 Participants Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 350 mg+LDAC n=8 Participants Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 400 mg+LDAC n=3 Participants Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule B. Volasertib 150 mg n=11 Participants Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 200 mg n=2 Participants Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 350 mg n=5 Participants Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 400 mg n=6 Participants Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 450 mg n=23 Participants Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 500 mg n=5 Participants Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 550 mg n=4 Participants Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase II Schedule C. LDAC n=45 Participants Low-dose cytarabine (LDAC) monotherapy 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Phase II Schedule A. Volasertib 350 mg+LDAC n=42 Participants Volasertib 350 milligram (mg) on Days 1 and 15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Total n=175 Participants Total of all reporting groups
Age, Continuous	69.5 Years STANDARD_DEVIATION 12.1 • n=5 Participants	67.0 Years STANDARD_DEVIATION 3.0 • n=7 Participants	71.2 Years STANDARD_DEVIATION 6.8 • n=5 Participants	67.9 Years STANDARD_DEVIATION 12.0 • n=4 Participants	72.5 Years STANDARD_DEVIATION 6.1 • n=21 Participants	73.3 Years STANDARD_DEVIATION 7.6 • n=10 Participants	73.5 Years STANDARD_DEVIATION 3.9 • n=115 Participants	73.0 Years STANDARD_DEVIATION 4.2 • n=6 Participants	70.6 Years STANDARD_DEVIATION 2.9 • n=6 Participants	65.2 Years STANDARD_DEVIATION 20.1 • n=64 Participants	68.2 Years STANDARD_DEVIATION 7.7 • n=17 Participants	66.4 Years STANDARD_DEVIATION 7.3 • n=21 Participants	69.8 Years STANDARD_DEVIATION 4.1 • n=22 Participants	75.2 Years STANDARD_DEVIATION 5.5 • n=8 Participants	75.6 Years STANDARD_DEVIATION 4.9 • n=16 Participants	72.5 Years STANDARD_DEVIATION 7.7 • n=135 Participants
Sex: Female, Male Female	2 Participants n=5 Participants	0 Participants n=7 Participants	2 Participants n=5 Participants	3 Participants n=4 Participants	3 Participants n=21 Participants	1 Participants n=10 Participants	3 Participants n=115 Participants	1 Participants n=6 Participants	3 Participants n=6 Participants	2 Participants n=64 Participants	16 Participants n=17 Participants	1 Participants n=21 Participants	3 Participants n=22 Participants	20 Participants n=8 Participants	19 Participants n=16 Participants	79 Participants n=135 Participants
Sex: Female, Male Male	2 Participants n=5 Participants	3 Participants n=7 Participants	3 Participants n=5 Participants	6 Participants n=4 Participants	5 Participants n=21 Participants	2 Participants n=10 Participants	8 Participants n=115 Participants	1 Participants n=6 Participants	2 Participants n=6 Participants	4 Participants n=64 Participants	7 Participants n=17 Participants	4 Participants n=21 Participants	1 Participants n=22 Participants	25 Participants n=8 Participants	23 Participants n=16 Participants	96 Participants n=135 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants	0 Participants n=21 Participants	0 Participants n=22 Participants	1 Participants n=8 Participants	0 Participants n=16 Participants	1 Participants n=135 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants	0 Participants n=21 Participants	0 Participants n=22 Participants	1 Participants n=8 Participants	1 Participants n=16 Participants	4 Participants n=135 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants	0 Participants n=21 Participants	0 Participants n=22 Participants	0 Participants n=8 Participants	0 Participants n=16 Participants	0 Participants n=135 Participants
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants	0 Participants n=21 Participants	0 Participants n=22 Participants	0 Participants n=8 Participants	0 Participants n=16 Participants	0 Participants n=135 Participants
Race (NIH/OMB) White	4 Participants n=5 Participants	3 Participants n=7 Participants	4 Participants n=5 Participants	8 Participants n=4 Participants	8 Participants n=21 Participants	3 Participants n=10 Participants	11 Participants n=115 Participants	2 Participants n=6 Participants	5 Participants n=6 Participants	6 Participants n=64 Participants	21 Participants n=17 Participants	5 Participants n=21 Participants	4 Participants n=22 Participants	35 Participants n=8 Participants	34 Participants n=16 Participants	153 Participants n=135 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	0 Participants n=17 Participants	0 Participants n=21 Participants	0 Participants n=22 Participants	0 Participants n=8 Participants	0 Participants n=16 Participants	0 Participants n=135 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	0 Participants n=6 Participants	0 Participants n=64 Participants	2 Participants n=17 Participants	0 Participants n=21 Participants	0 Participants n=22 Participants	8 Participants n=8 Participants	7 Participants n=16 Participants	17 Participants n=135 Participants

PRIMARY outcome

Timeframe: First Treatment cycle, up to 28 days.

Population: Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib (BI 6727) or LDAC (Low-Dose Cytarabine), including patients who were replaced for any reason.

Outcome measures

Outcome measures
Measure	Phase I Schedule A. Volasertib+LDAC n=32 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and LDAC 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle until the patient met criteria for stopping study medication during the MTD evaluation period.	Phase I Schedule B. Volasertib n=56 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) until the patient met criteria for stopping study medication during the MTD evaluation period	Phase I Schedule A. Volasertib 250 mg+LDAC Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 300 mg+LDAC Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 400 mg+LDAC Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Total Phase I Combined. Schedule A. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps up to 400 mg, with a starting dose of 400 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes and LDAC 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule B. Volasertib 150 mg Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 200 mg Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 350 mg Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 400 mg Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 450 mg Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 500 mg Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 550 mg Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Total Phase I Combined. Schedule B. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps from an initial starting dose of 150 mg. Dose was escalated up to 550 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes.	Phase II Schedule C. LDAC Low-dose cytarabine (LDAC) monotherapy 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Phase II Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) on Days 1 and 15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Total Phase II Combined. Schedule A and C. Volasertib escalating dose on Days 1 and 15 (28-day cycle). Dose escalation in 50 milligram (mg) steps up to 400 mg, with a starting dose of 150 mg. Volasertib 350 mg on Days 1+15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Phase I: Maximum Tolerated Dose (MTD) of Volasertib in Combination With LDAC (Schedule A) and Volasertib Monotherapy (Schedule B)	350 milligram (mg)	450 milligram (mg)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: The best overall response recorded during the time period from the start of the treatment until end of the treatment period, progression or death (whichever was earlier), up to 869 days.

Population: Treated set-phase II part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.

Phase II: Number of patients with Objective Response (Complete remission (CR) + Complete remission with incomplete blood count recovery (CRi)). Complete remission (CR): morphologically leukaemia-free state (i.e. bone marrow with \<5% blasts by morphologic criteria and no Auer rods, no evidence of extramedullary leukaemia) and absolute neutrophil count ≥1,000/microliter (μL) and platelets \>100,000/μL. Complete remission with incomplete blood count recovery ("incomplete" CR, CRi): all of the above criteria for CR were met except that neutrophils \<1,000/μL or platelets \<100,000/μL in the blood were not achieved.

Outcome measures

Outcome measures
Measure	Phase I Schedule A. Volasertib+LDAC n=45 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and LDAC 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle until the patient met criteria for stopping study medication during the MTD evaluation period.	Phase I Schedule B. Volasertib n=42 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) until the patient met criteria for stopping study medication during the MTD evaluation period	Phase I Schedule A. Volasertib 250 mg+LDAC Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 300 mg+LDAC Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 400 mg+LDAC Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Total Phase I Combined. Schedule A. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps up to 400 mg, with a starting dose of 400 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes and LDAC 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule B. Volasertib 150 mg Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 200 mg Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 350 mg Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 400 mg Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 450 mg Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 500 mg Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 550 mg Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Total Phase I Combined. Schedule B. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps from an initial starting dose of 150 mg. Dose was escalated up to 550 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes.	Phase II Schedule C. LDAC Low-dose cytarabine (LDAC) monotherapy 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Phase II Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) on Days 1 and 15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Total Phase II Combined. Schedule A and C. Volasertib escalating dose on Days 1 and 15 (28-day cycle). Dose escalation in 50 milligram (mg) steps up to 400 mg, with a starting dose of 150 mg. Volasertib 350 mg on Days 1+15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Phase II: Number of Patients With Objective Response (Complete Remission (CR) + Complete Remission With Incomplete Blood Count Recovery (CRi))	6 Participants	13 Participants	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: First Treatment cycle, up to 28 days.

Population: Treated Set-Phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib (BI 6727) or LDAC (Low-Dose Cytarabine), including patients who were replaced for any reason.

A DLT was defined as a drug related CTCAE (Common Toxicity Criteria for Adverse Events) Grade ≥3 non-haematological toxicity (excluding untreated nausea, untreated vomiting, Grade 3 untreated diarrhea, Grade 3 febrile neutropenia, and Grade 3 infection with Grade 3 or 4 neutrophils). In patients with CRi (Complete Remission with Incomplete Blood Count Recovery) or PR (Partial Remission), persistent Grade 4 neutropenia or thrombocytopenia for 3 weeks after the end of the treatment cycle was regarded as a DLT unless the respective Grade 4 cytopenia was preexistent. In patients who required platelet substitution to maintain a Grade \<4 before treatment, a Grade 4 thrombocytopenia after treatment did not constitute a DLT.

Outcome measures

Outcome measures
Measure	Phase I Schedule A. Volasertib+LDAC n=4 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and LDAC 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle until the patient met criteria for stopping study medication during the MTD evaluation period.	Phase I Schedule B. Volasertib n=3 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) until the patient met criteria for stopping study medication during the MTD evaluation period	Phase I Schedule A. Volasertib 250 mg+LDAC n=5 Participants Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 300 mg+LDAC n=9 Participants Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 350 mg+LDAC n=8 Participants Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 400 mg+LDAC n=3 Participants Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Total Phase I Combined. Schedule A. n=32 Participants Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps up to 400 mg, with a starting dose of 400 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes and LDAC 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule B. Volasertib 150 mg n=11 Participants Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 200 mg n=2 Participants Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 350 mg n=5 Participants Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 400 mg n=6 Participants Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 450 mg n=23 Participants Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 500 mg n=5 Participants Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 550 mg n=4 Participants Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Total Phase I Combined. Schedule B. n=56 Participants Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps from an initial starting dose of 150 mg. Dose was escalated up to 550 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes.	Phase II Schedule C. LDAC Low-dose cytarabine (LDAC) monotherapy 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Phase II Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) on Days 1 and 15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Total Phase II Combined. Schedule A and C. Volasertib escalating dose on Days 1 and 15 (28-day cycle). Dose escalation in 50 milligram (mg) steps up to 400 mg, with a starting dose of 150 mg. Volasertib 350 mg on Days 1+15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Phase I: Number of Participants With Dose Limiting Toxicities (DLTs) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD)	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants	2 Participants	4 Participants	1 Participants	0 Participants	0 Participants	1 Participants	1 Participants	2 Participants	2 Participants	7 Participants	—	—	—

SECONDARY outcome

Timeframe: The best overall response recorded during the time period from the start of the treatment until end of the treatment period, progression or death (whichever was earlier), up to 869 days.

Population: Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC, including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.

* CR * CR+CRi * Partial remission: CR except bone marrow (BM) contained ≥5% but \<25% blasts (or ≤50% initial blasts), or \<5% blasts in presence of Auer rods or abnormal morphology. * No change: survived ≥7 days (d) after 1st cycle with persistent leukemia in last peripheral blood smear or BM, or with persistent extramedullary disease, without further deterioration due to leukemia or increase of blasts in BM or peripheral blood. * Aplasia: survived ≥7d after 1st cycle, died whilst cytopenic, with last post-treatment BM result aplastic or hypoplastic and without leukemia blasts. * Indeterminate: survived \<7 d after 1st cycle or survived ≥7d after 1st cycle, died with no persistent leukemia in peripheral smear but no post-treatment BM examination or did not complete 1st cycle. * Progressive disease: survived ≥7d after 1st cycle with increase of blast population in BM or peripheral blood or aggravation or new extramedullary disease or further deterioration or death due to leukemia.

Outcome measures

Outcome measures
Measure	Phase I Schedule A. Volasertib+LDAC n=4 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and LDAC 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle until the patient met criteria for stopping study medication during the MTD evaluation period.	Phase I Schedule B. Volasertib n=3 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) until the patient met criteria for stopping study medication during the MTD evaluation period	Phase I Schedule A. Volasertib 250 mg+LDAC n=5 Participants Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 300 mg+LDAC n=9 Participants Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 350 mg+LDAC n=8 Participants Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 400 mg+LDAC n=3 Participants Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Total Phase I Combined. Schedule A. n=32 Participants Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps up to 400 mg, with a starting dose of 400 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes and LDAC 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule B. Volasertib 150 mg n=11 Participants Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 200 mg n=2 Participants Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 350 mg n=5 Participants Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 400 mg n=6 Participants Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 450 mg n=23 Participants Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 500 mg n=5 Participants Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 550 mg n=4 Participants Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Total Phase I Combined. Schedule B. n=56 Participants Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps from an initial starting dose of 150 mg. Dose was escalated up to 550 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes.	Phase II Schedule C. LDAC n=45 Participants Low-dose cytarabine (LDAC) monotherapy 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Phase II Schedule A. Volasertib 350 mg+LDAC n=42 Participants Volasertib 350 milligram (mg) on Days 1 and 15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Total Phase II Combined. Schedule A and C. n=87 Participants Volasertib escalating dose on Days 1 and 15 (28-day cycle). Dose escalation in 50 milligram (mg) steps up to 400 mg, with a starting dose of 150 mg. Volasertib 350 mg on Days 1+15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Best Overall Response Complete remission	0 Participants	0 Participants	2 Participants	0 Participants	0 Participants	0 Participants	2 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	3 Participants	6 Participants	9 Participants
Best Overall Response CRi	0 Participants	2 Participants	0 Participants	1 Participants	1 Participants	0 Participants	4 Participants	0 Participants	0 Participants	1 Participants	2 Participants	2 Participants	0 Participants	0 Participants	5 Participants	3 Participants	7 Participants	10 Participants
Best Overall Response Partial remission	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	2 Participants	0 Participants	1 Participants	4 Participants	2 Participants	2 Participants	4 Participants
Best Overall Response No change	2 Participants	1 Participants	2 Participants	1 Participants	1 Participants	1 Participants	8 Participants	4 Participants	0 Participants	2 Participants	2 Participants	7 Participants	3 Participants	0 Participants	18 Participants	18 Participants	15 Participants	33 Participants
Best Overall Response Aplasia	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	3 Participants	1 Participants	1 Participants	6 Participants	0 Participants	0 Participants	0 Participants
Best Overall Response Indeterminate	0 Participants	0 Participants	0 Participants	2 Participants	3 Participants	1 Participants	6 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	3 Participants	5 Participants	8 Participants
Best Overall Response Progressive disease	2 Participants	0 Participants	1 Participants	3 Participants	3 Participants	1 Participants	10 Participants	6 Participants	2 Participants	1 Participants	1 Participants	7 Participants	1 Participants	1 Participants	19 Participants	14 Participants	7 Participants	21 Participants
Best Overall Response Not evaluable	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	2 Participants	0 Participants	1 Participants	3 Participants	2 Participants	0 Participants	2 Participants
Best Overall Response Missing	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: The best overall response recorded during the time period from the start of the treatment until end of the treatment period, progression or death (whichever was earlier), up to 594 days.

Population: Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC, including patients who were replaced for any reason.

Phase I: Number of patients with Objective Response (Complete remission (CR) + Complete remission with incomplete blood count recovery (CRi)). Complete remission (CR): morphologically leukaemia-free state (i.e. bone marrow with \<5% blasts by morphologic criteria and no Auer rods, no evidence of extramedullary leukaemia) and absolute neutrophil count ≥1,000/microliter (μL) and platelets \>100,000/μL. Complete remission with incomplete blood count recovery ("incomplete" CR, CRi): all of the above criteria for CR were met except that neutrophils \<1,000/μL or platelets \<100,000/μL in the blood were not achieved.

Outcome measures

Outcome measures
Measure	Phase I Schedule A. Volasertib+LDAC n=4 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and LDAC 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle until the patient met criteria for stopping study medication during the MTD evaluation period.	Phase I Schedule B. Volasertib n=3 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) until the patient met criteria for stopping study medication during the MTD evaluation period	Phase I Schedule A. Volasertib 250 mg+LDAC n=5 Participants Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 300 mg+LDAC n=9 Participants Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 350 mg+LDAC n=8 Participants Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 400 mg+LDAC n=3 Participants Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Total Phase I Combined. Schedule A. n=32 Participants Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps up to 400 mg, with a starting dose of 400 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes and LDAC 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule B. Volasertib 150 mg n=11 Participants Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 200 mg n=2 Participants Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 350 mg n=5 Participants Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 400 mg n=6 Participants Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 450 mg n=23 Participants Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 500 mg n=5 Participants Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 550 mg n=4 Participants Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Total Phase I Combined. Schedule B. n=56 Participants Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps from an initial starting dose of 150 mg. Dose was escalated up to 550 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes.	Phase II Schedule C. LDAC Low-dose cytarabine (LDAC) monotherapy 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Phase II Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) on Days 1 and 15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Total Phase II Combined. Schedule A and C. Volasertib escalating dose on Days 1 and 15 (28-day cycle). Dose escalation in 50 milligram (mg) steps up to 400 mg, with a starting dose of 150 mg. Volasertib 350 mg on Days 1+15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Phase I: Number of Patients With Objective Response: Complete Remission or Complete Remission With Incomplete Blood Count Recovery (CR+CRi)	0 Participants	2 Participants	2 Participants	1 Participants	1 Participants	0 Participants	6 Participants	0 Participants	0 Participants	1 Participants	2 Participants	2 Participants	0 Participants	0 Participants	5 Participants	—	—	—

SECONDARY outcome

Timeframe: The patients that entered the trial, and measured from the date of randomization to the date of disease progression (treatment failure), relapse or death from any cause, whichever occurred first, up to 1000 days..

Population: Treated Set-Phase II part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.

Event-free survival (EFS) \[days\] was the shortest duration of the following: (a) Date of assessment indicating PD on the response page of the eCRF (Electronic Case Report Form) - date of randomisation + 1 day (b) Date of assessment indicating clinical progressive disease (PD) on the disease or responses pages of the of eCRF- date of randomisation + 1 day (c) Date of assessment indicating PD on the patient status page of the eCRF - date of randomisation +1 day (for patients who had not been censored before this time point) (d) Death date - date of randomisation +1 day Patients not being assessed PD, clinical PD, or death during the trial were censored. EFS was analysed with the Kaplan-Meier method for each of the treatment arms.

Outcome measures

Outcome measures
Measure	Phase I Schedule A. Volasertib+LDAC n=45 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and LDAC 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle until the patient met criteria for stopping study medication during the MTD evaluation period.	Phase I Schedule B. Volasertib n=42 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) until the patient met criteria for stopping study medication during the MTD evaluation period	Phase I Schedule A. Volasertib 250 mg+LDAC Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 300 mg+LDAC Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 400 mg+LDAC Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Total Phase I Combined. Schedule A. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps up to 400 mg, with a starting dose of 400 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes and LDAC 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule B. Volasertib 150 mg Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 200 mg Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 350 mg Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 400 mg Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 450 mg Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 500 mg Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 550 mg Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Total Phase I Combined. Schedule B. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps from an initial starting dose of 150 mg. Dose was escalated up to 550 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes.	Phase II Schedule C. LDAC Low-dose cytarabine (LDAC) monotherapy 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Phase II Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) on Days 1 and 15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Total Phase II Combined. Schedule A and C. Volasertib escalating dose on Days 1 and 15 (28-day cycle). Dose escalation in 50 milligram (mg) steps up to 400 mg, with a starting dose of 150 mg. Volasertib 350 mg on Days 1+15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Phase II: Event Free Survival	69.0 Days Interval 27.0 to 215.0	169.0 Days Interval 39.0 to 470.0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: The patients that entered the trial, and measured from the date of randomisation until death from any cause, up to 1100 days..

Population: Treated Set-Phase II part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.

Overall survival \[days\] = (date of death - date of randomisation + 1 day), for patients with known date of death. Overall survival (censored) \[days\] = (date of last trial visit or follow-up - date of randomisation + 1 day), for patients who were still alive at time of database lock. Overall survival (OS) was analysed with the Kaplan-Meier method for each of the treatment arms.

Outcome measures

Outcome measures
Measure	Phase I Schedule A. Volasertib+LDAC n=45 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and LDAC 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle until the patient met criteria for stopping study medication during the MTD evaluation period.	Phase I Schedule B. Volasertib n=42 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) until the patient met criteria for stopping study medication during the MTD evaluation period	Phase I Schedule A. Volasertib 250 mg+LDAC Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 300 mg+LDAC Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 400 mg+LDAC Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Total Phase I Combined. Schedule A. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps up to 400 mg, with a starting dose of 400 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes and LDAC 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule B. Volasertib 150 mg Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 200 mg Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 350 mg Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 400 mg Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 450 mg Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 500 mg Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 550 mg Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Total Phase I Combined. Schedule B. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps from an initial starting dose of 150 mg. Dose was escalated up to 550 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes.	Phase II Schedule C. LDAC Low-dose cytarabine (LDAC) monotherapy 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Phase II Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) on Days 1 and 15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Total Phase II Combined. Schedule A and C. Volasertib escalating dose on Days 1 and 15 (28-day cycle). Dose escalation in 50 milligram (mg) steps up to 400 mg, with a starting dose of 150 mg. Volasertib 350 mg on Days 1+15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Phase II: Overall Survival	158.0 Days Interval 78.0 to 347.0	245.0 Days Interval 73.0 to 689.0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: The patients who achieved CR or CRi, and was measured from the date of attaining CR or CRi until the date of disease recurrence or death from any cause, whichever occurred first, up to 900 days.

Population: Patients in Treated Set-Phase II with objective response. Treated Set-Phase II part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.

Relapse-free survival \[days\] = (date of first recurrence of disease or death after entering the trial - date of first occurrence of CR or CRi after entering the trial+ 1 day) for patients with a recurrence (this value should be positive). Relapse-free survival (censored) \[days\] = (date of last trial visit or follow-up - date of first occurrence of CR or CRi after entering the trial + 1 day) for patients who did not experience recurrence of disease or death at the time of analysis.

Outcome measures

Outcome measures
Measure	Phase I Schedule A. Volasertib+LDAC n=6 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and LDAC 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle until the patient met criteria for stopping study medication during the MTD evaluation period.	Phase I Schedule B. Volasertib n=13 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) until the patient met criteria for stopping study medication during the MTD evaluation period	Phase I Schedule A. Volasertib 250 mg+LDAC Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 300 mg+LDAC Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 400 mg+LDAC Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Total Phase I Combined. Schedule A. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps up to 400 mg, with a starting dose of 400 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes and LDAC 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule B. Volasertib 150 mg Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 200 mg Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 350 mg Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 400 mg Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 450 mg Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 500 mg Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 550 mg Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Total Phase I Combined. Schedule B. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps from an initial starting dose of 150 mg. Dose was escalated up to 550 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes.	Phase II Schedule C. LDAC Low-dose cytarabine (LDAC) monotherapy 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Phase II Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) on Days 1 and 15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Total Phase II Combined. Schedule A and C. Volasertib escalating dose on Days 1 and 15 (28-day cycle). Dose escalation in 50 milligram (mg) steps up to 400 mg, with a starting dose of 150 mg. Volasertib 350 mg on Days 1+15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Phase II: Relapse - Free Survival	304.0 Days Interval 113.0 to 367.0	563.0 Days Interval 427.0 to 25% quartile not reached, not enough events occurred.	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: The patients who achieved CR or CRi, and was measured from the date of attaining CR or CRi until the date of disease recurrence (relapse), up to 900 days.

Remission duration analysis was defined only for patients who achieved Complete remission (CR) or Complete remission with incomplete blood count recovery (CRi), and was measured from the date of attaining CR or CRi until the date of disease recurrence (relapse). For patients who died without report of relapse, remission duration was censored on the date of death, regardless of cause.

Outcome measures

Outcome measures
Measure	Phase I Schedule A. Volasertib+LDAC n=6 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and LDAC 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle until the patient met criteria for stopping study medication during the MTD evaluation period.	Phase I Schedule B. Volasertib n=13 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) until the patient met criteria for stopping study medication during the MTD evaluation period	Phase I Schedule A. Volasertib 250 mg+LDAC Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 300 mg+LDAC Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 400 mg+LDAC Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Total Phase I Combined. Schedule A. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps up to 400 mg, with a starting dose of 400 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes and LDAC 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule B. Volasertib 150 mg Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 200 mg Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 350 mg Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 400 mg Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 450 mg Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 500 mg Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 550 mg Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Total Phase I Combined. Schedule B. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps from an initial starting dose of 150 mg. Dose was escalated up to 550 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes.	Phase II Schedule C. LDAC Low-dose cytarabine (LDAC) monotherapy 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Phase II Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) on Days 1 and 15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Total Phase II Combined. Schedule A and C. Volasertib escalating dose on Days 1 and 15 (28-day cycle). Dose escalation in 50 milligram (mg) steps up to 400 mg, with a starting dose of 150 mg. Volasertib 350 mg on Days 1+15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Phase II: Remission Duration	367.0 Days Interval 113.0 to 367.0	687.0 Days Interval 427.0 to 25% quartile not reached, not enough events occurred.	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: The patients who achieved CR or CRi, and was measured from the date of attaining CR or CRi until the date of disease recurrence (relapse), up to 158 days.

Time to remission \[days\] = (date of first occurrence of CR or CRi after entering the trial-date of randomisation + 1 day) for patients with an objective response.

Outcome measures

Outcome measures
Measure	Phase I Schedule A. Volasertib+LDAC n=6 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and LDAC 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle until the patient met criteria for stopping study medication during the MTD evaluation period.	Phase I Schedule B. Volasertib n=13 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) until the patient met criteria for stopping study medication during the MTD evaluation period	Phase I Schedule A. Volasertib 250 mg+LDAC Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 300 mg+LDAC Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 400 mg+LDAC Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Total Phase I Combined. Schedule A. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps up to 400 mg, with a starting dose of 400 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes and LDAC 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule B. Volasertib 150 mg Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 200 mg Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 350 mg Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 400 mg Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 450 mg Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 500 mg Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 550 mg Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Total Phase I Combined. Schedule B. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps from an initial starting dose of 150 mg. Dose was escalated up to 550 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes.	Phase II Schedule C. LDAC Low-dose cytarabine (LDAC) monotherapy 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Phase II Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) on Days 1 and 15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Total Phase II Combined. Schedule A and C. Volasertib escalating dose on Days 1 and 15 (28-day cycle). Dose escalation in 50 milligram (mg) steps up to 400 mg, with a starting dose of 150 mg. Volasertib 350 mg on Days 1+15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Phase II: Time to Remission	63.5 Days Interval 30.0 to 125.0	71.0 Days Interval 29.0 to 158.0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Baseline and End of Treatment (up to 869 days).

Population: Treated Set-Phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC, including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC. Only participants with non-missing values are reported.

ECOG performance score change from baseline to last visit of last cycle = ECOG performance score at last visit of the last cycle - ECOG performance score at baseline. ECOG performance score changes from baseline were also categorised on a 3-point categorical scale: deteriorated (-1), unchanged (0), and improved (1). The number of participants for category of ECOG score change is reported.

Outcome measures

Outcome measures
Measure	Phase I Schedule A. Volasertib+LDAC n=4 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and LDAC 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle until the patient met criteria for stopping study medication during the MTD evaluation period.	Phase I Schedule B. Volasertib n=3 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) until the patient met criteria for stopping study medication during the MTD evaluation period	Phase I Schedule A. Volasertib 250 mg+LDAC n=5 Participants Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 300 mg+LDAC n=5 Participants Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 350 mg+LDAC n=8 Participants Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 400 mg+LDAC n=2 Participants Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Total Phase I Combined. Schedule A. n=27 Participants Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps up to 400 mg, with a starting dose of 400 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes and LDAC 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule B. Volasertib 150 mg n=10 Participants Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 200 mg n=2 Participants Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 350 mg n=5 Participants Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 400 mg n=6 Participants Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 450 mg n=22 Participants Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 500 mg n=5 Participants Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 550 mg n=3 Participants Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Total Phase I Combined. Schedule B. n=53 Participants Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps from an initial starting dose of 150 mg. Dose was escalated up to 550 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes.	Phase II Schedule C. LDAC n=42 Participants Low-dose cytarabine (LDAC) monotherapy 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Phase II Schedule A. Volasertib 350 mg+LDAC n=39 Participants Volasertib 350 milligram (mg) on Days 1 and 15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Total Phase II Combined. Schedule A and C. n=81 Participants Volasertib escalating dose on Days 1 and 15 (28-day cycle). Dose escalation in 50 milligram (mg) steps up to 400 mg, with a starting dose of 150 mg. Volasertib 350 mg on Days 1+15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Best Eastern Co-operative Oncology Group (ECOG) Performance Score From Baseline Until End of Treatment Unchanged	3 Participants	1 Participants	5 Participants	2 Participants	5 Participants	1 Participants	17 Participants	9 Participants	1 Participants	0 Participants	4 Participants	14 Participants	2 Participants	3 Participants	33 Participants	22 Participants	15 Participants	37 Participants
Best Eastern Co-operative Oncology Group (ECOG) Performance Score From Baseline Until End of Treatment Improved	0 Participants	2 Participants	0 Participants	1 Participants	0 Participants	0 Participants	3 Participants	0 Participants	0 Participants	1 Participants	1 Participants	3 Participants	1 Participants	0 Participants	6 Participants	8 Participants	13 Participants	21 Participants
Best Eastern Co-operative Oncology Group (ECOG) Performance Score From Baseline Until End of Treatment Deteriorated	1 Participants	0 Participants	0 Participants	2 Participants	3 Participants	1 Participants	7 Participants	1 Participants	1 Participants	4 Participants	1 Participants	5 Participants	2 Participants	0 Participants	14 Participants	12 Participants	11 Participants	23 Participants

SECONDARY outcome

Timeframe: Cycle 1: -0:05 hour (h), 0:30h, 1:00h, 1:30h, 2h, 3h, 4h, 24h, 96h, 216h, 335:55h, 336:30h, 337h, 337:30h, 338h, 339h, 340h, 648h after first drug administration.

Population: Pharmacokinetic (PK) set which included all patients in the treated set who had at least 1 evaluable blood sample during cycle 1. Phase I Schedule B Volasertib 200mg+LDAC was not analysed as there was not enough plasma concentrations at the terminal phase of the curve to calculate the half-life for one of the two subjects.

Total Clearance (CL) of Volasertib in Plasma after Intravenous (i.v.) Administration of Volasertib.

Outcome measures

Outcome measures
Measure	Phase I Schedule A. Volasertib+LDAC n=4 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and LDAC 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle until the patient met criteria for stopping study medication during the MTD evaluation period.	Phase I Schedule B. Volasertib n=3 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) until the patient met criteria for stopping study medication during the MTD evaluation period	Phase I Schedule A. Volasertib 250 mg+LDAC n=5 Participants Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 300 mg+LDAC n=8 Participants Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 350 mg+LDAC n=8 Participants Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 400 mg+LDAC n=3 Participants Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Total Phase I Combined. Schedule A. n=10 Participants Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps up to 400 mg, with a starting dose of 400 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes and LDAC 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule B. Volasertib 150 mg n=1 Participants Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 200 mg n=5 Participants Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 350 mg n=6 Participants Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 400 mg n=22 Participants Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 450 mg n=5 Participants Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 500 mg n=3 Participants Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 550 mg n=31 Participants Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Total Phase I Combined. Schedule B. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps from an initial starting dose of 150 mg. Dose was escalated up to 550 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes.	Phase II Schedule C. LDAC Low-dose cytarabine (LDAC) monotherapy 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Phase II Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) on Days 1 and 15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Total Phase II Combined. Schedule A and C. Volasertib escalating dose on Days 1 and 15 (28-day cycle). Dose escalation in 50 milligram (mg) steps up to 400 mg, with a starting dose of 150 mg. Volasertib 350 mg on Days 1+15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Total Clearance (CL) of Volasertib in Plasma After i.v (Intravenous) Administration of Volasertib	1280 millilitre/minute (mL/min) Geometric Coefficient of Variation 52.8	972 millilitre/minute (mL/min) Geometric Coefficient of Variation 26.6	864 millilitre/minute (mL/min) Geometric Coefficient of Variation 27.6	1150 millilitre/minute (mL/min) Geometric Coefficient of Variation 34.4	1000 millilitre/minute (mL/min) Geometric Coefficient of Variation 36.2	852 millilitre/minute (mL/min) Geometric Coefficient of Variation 49.6	1330 millilitre/minute (mL/min) Geometric Coefficient of Variation 29.3	NA millilitre/minute (mL/min) Geometric Coefficient of Variation NA Not calculable with one subject	810 millilitre/minute (mL/min) Geometric Coefficient of Variation 35.1	1120 millilitre/minute (mL/min) Geometric Coefficient of Variation 62.1	920 millilitre/minute (mL/min) Geometric Coefficient of Variation 36.2	1140 millilitre/minute (mL/min) Geometric Coefficient of Variation 38.5	939 millilitre/minute (mL/min) Geometric Coefficient of Variation 93.2	897 millilitre/minute (mL/min) Geometric Coefficient of Variation 42.8	—	—	—	—

SECONDARY outcome

Timeframe: Cycle 1: -0:05 hour (h), 0:30h, 1:00h, 1:30h, 2h, 3h, 4h, 24h, 96h, 216h, 335:55h, 336:30h, 337h, 337:30h, 338h, 339h, 340h, 648h after first drug administration.

Apparent Volume of Distribution of volasertib at steady state (VSS) following Intravenous (i.v.) administration.

Outcome measures

Outcome measures
Measure	Phase I Schedule A. Volasertib+LDAC n=4 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and LDAC 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle until the patient met criteria for stopping study medication during the MTD evaluation period.	Phase I Schedule B. Volasertib n=3 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) until the patient met criteria for stopping study medication during the MTD evaluation period	Phase I Schedule A. Volasertib 250 mg+LDAC n=5 Participants Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 300 mg+LDAC n=8 Participants Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 350 mg+LDAC n=8 Participants Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 400 mg+LDAC n=3 Participants Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Total Phase I Combined. Schedule A. n=10 Participants Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps up to 400 mg, with a starting dose of 400 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes and LDAC 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule B. Volasertib 150 mg n=1 Participants Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 200 mg n=5 Participants Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 350 mg n=6 Participants Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 400 mg n=22 Participants Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 450 mg n=5 Participants Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 500 mg n=3 Participants Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 550 mg n=31 Participants Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Total Phase I Combined. Schedule B. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps from an initial starting dose of 150 mg. Dose was escalated up to 550 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes.	Phase II Schedule C. LDAC Low-dose cytarabine (LDAC) monotherapy 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Phase II Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) on Days 1 and 15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Total Phase II Combined. Schedule A and C. Volasertib escalating dose on Days 1 and 15 (28-day cycle). Dose escalation in 50 milligram (mg) steps up to 400 mg, with a starting dose of 150 mg. Volasertib 350 mg on Days 1+15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Apparent Volume of Distribution of Volasertib at Steady State (VSS)	10600 Liter (L) Geometric Coefficient of Variation 111.0	8640 Liter (L) Geometric Coefficient of Variation 14.1	7000 Liter (L) Geometric Coefficient of Variation 26.6	6320 Liter (L) Geometric Coefficient of Variation 35.9	5270 Liter (L) Geometric Coefficient of Variation 58.2	4830 Liter (L) Geometric Coefficient of Variation 56.7	10300 Liter (L) Geometric Coefficient of Variation 36.3	NA Liter (L) Geometric Coefficient of Variation NA Not calculable with one subject	5800 Liter (L) Geometric Coefficient of Variation 35.1	7150 Liter (L) Geometric Coefficient of Variation 70.6	5740 Liter (L) Geometric Coefficient of Variation 38.7	6360 Liter (L) Geometric Coefficient of Variation 50.1	5680 Liter (L) Geometric Coefficient of Variation 81.9	6130 Liter (L) Geometric Coefficient of Variation 42.0	—	—	—	—

SECONDARY outcome

Timeframe: Cycle 1: -0:05 hour (h), 0:30h, 1:00h, 1:30h, 2h, 3h, 4h, 24h, 96h, 216h, 335:55h, 336:30h, 337h, 337:30h, 338h, 339h, 340h, 648h after first drug administration.

Population: Pharmacokinetic (PK) set which included all patients in the treated set who had at least 1 evaluable blood sample during cycle 1, Only participants with non-missing values are reported.

Cmax, norm: Maximum measured concentration of Cytarabine in plasma. The dose normalisation was done by dividing by the dose applied. Unit: nanogram/milliliter/milligram: ((ng/mL)/mg). Dose groups of Phase I were combined by dose normalizing as pre specified in the study protocol.

Outcome measures

Outcome measures
Measure	Phase I Schedule A. Volasertib+LDAC n=32 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and LDAC 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle until the patient met criteria for stopping study medication during the MTD evaluation period.	Phase I Schedule B. Volasertib n=41 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) until the patient met criteria for stopping study medication during the MTD evaluation period	Phase I Schedule A. Volasertib 250 mg+LDAC n=40 Participants Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 300 mg+LDAC Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 400 mg+LDAC Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Total Phase I Combined. Schedule A. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps up to 400 mg, with a starting dose of 400 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes and LDAC 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule B. Volasertib 150 mg Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 200 mg Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 350 mg Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 400 mg Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 450 mg Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 500 mg Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 550 mg Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Total Phase I Combined. Schedule B. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps from an initial starting dose of 150 mg. Dose was escalated up to 550 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes.	Phase II Schedule C. LDAC Low-dose cytarabine (LDAC) monotherapy 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Phase II Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) on Days 1 and 15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Total Phase II Combined. Schedule A and C. Volasertib escalating dose on Days 1 and 15 (28-day cycle). Dose escalation in 50 milligram (mg) steps up to 400 mg, with a starting dose of 150 mg. Volasertib 350 mg on Days 1+15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Dose Normalized Maximum Measured Concentration of Cytarabine in Plasma (Cmax, Norm)	2.92 (ng/mL)/mg Geometric Coefficient of Variation 61.3	2.83 (ng/mL)/mg Geometric Coefficient of Variation 52.8	2.36 (ng/mL)/mg Geometric Coefficient of Variation 77.6	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Cycle 1: -0:05 hour (h), 0:30h, 1:00h, 1:30h, 2h, 3h, 4h after first drug administration.

Population: Pharmacokinetic (PK) set which included all patients in the treated set who had at least 1 evaluable blood sample during cycle 1.

AUC0-4,norm: Area under the concentration-time curve of Cytarabine in plasma over the time interval from zero extrapolated to 4 hours. The dose normalisation was done by dividing by dose applied. Unit: nanogram\*hour/milliliter/milligram: ((ng\*h/mL)/mg). Dose groups of Phase I were combined by dose normalizing as pre specified in the study protocol.

Outcome measures

Outcome measures
Measure	Phase I Schedule A. Volasertib+LDAC n=32 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and LDAC 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle until the patient met criteria for stopping study medication during the MTD evaluation period.	Phase I Schedule B. Volasertib n=41 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) until the patient met criteria for stopping study medication during the MTD evaluation period	Phase I Schedule A. Volasertib 250 mg+LDAC n=40 Participants Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 300 mg+LDAC Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 400 mg+LDAC Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Total Phase I Combined. Schedule A. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps up to 400 mg, with a starting dose of 400 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes and LDAC 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule B. Volasertib 150 mg Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 200 mg Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 350 mg Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 400 mg Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 450 mg Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 500 mg Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 550 mg Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Total Phase I Combined. Schedule B. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps from an initial starting dose of 150 mg. Dose was escalated up to 550 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes.	Phase II Schedule C. LDAC Low-dose cytarabine (LDAC) monotherapy 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Phase II Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) on Days 1 and 15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Total Phase II Combined. Schedule A and C. Volasertib escalating dose on Days 1 and 15 (28-day cycle). Dose escalation in 50 milligram (mg) steps up to 400 mg, with a starting dose of 150 mg. Volasertib 350 mg on Days 1+15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Dose Normalized Area Under the Concentration-Time Curve of Cytarabine in Plasma Over the Time Interval From 0 Extrapolated up to 4 Hours	3.84 (ng*h/mL)/mg Geometric Coefficient of Variation 30.6	4.00 (ng*h/mL)/mg Geometric Coefficient of Variation 35.6	3.94 (ng*h/mL)/mg Geometric Coefficient of Variation 43.8	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Baseline (Days -14 to -1) and day 1 (1 hour and 24 hours) after start of infusion.

ECG (Electro Cardio Gram) Measurements: Absolute QTcF (QT Interval (interval from the beginning of the QRS complex to the end of the T wave) Corrected for Heart Rate Using Fridericia's Formula) Intervals. The 350 mg + LDAC arm of phase I and II were combined into one arm to provide maximum information on QT changes and presented together with the Phase I schedule B 450 mg arm, as pre specified in the study protocol.

Outcome measures

Outcome measures
Measure	Phase I Schedule A. Volasertib+LDAC n=50 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and LDAC 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle until the patient met criteria for stopping study medication during the MTD evaluation period.	Phase I Schedule B. Volasertib n=23 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) until the patient met criteria for stopping study medication during the MTD evaluation period	Phase I Schedule A. Volasertib 250 mg+LDAC Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 300 mg+LDAC Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 400 mg+LDAC Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Total Phase I Combined. Schedule A. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps up to 400 mg, with a starting dose of 400 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes and LDAC 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule B. Volasertib 150 mg Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 200 mg Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 350 mg Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 400 mg Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 450 mg Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 500 mg Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 550 mg Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Total Phase I Combined. Schedule B. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps from an initial starting dose of 150 mg. Dose was escalated up to 550 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes.	Phase II Schedule C. LDAC Low-dose cytarabine (LDAC) monotherapy 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Phase II Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) on Days 1 and 15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Total Phase II Combined. Schedule A and C. Volasertib escalating dose on Days 1 and 15 (28-day cycle). Dose escalation in 50 milligram (mg) steps up to 400 mg, with a starting dose of 150 mg. Volasertib 350 mg on Days 1+15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Absolute QTcF (QT Interval Corrected for Heart Rate Using Fridericia's Formula) Intervals Individual baseline	411.6 milliseconds (ms) Standard Deviation 20.7	412.4 milliseconds (ms) Standard Deviation 18.7	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Absolute QTcF (QT Interval Corrected for Heart Rate Using Fridericia's Formula) Intervals 1 hour after start of infusion	430.0 milliseconds (ms) Standard Deviation 20.4	441.1 milliseconds (ms) Standard Deviation 20.0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Absolute QTcF (QT Interval Corrected for Heart Rate Using Fridericia's Formula) Intervals 24 hour after start of infusion	414.0 milliseconds (ms) Standard Deviation 21.3	411.9 milliseconds (ms) Standard Deviation 18.4	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Baseline (Days -14 to -1) and day 1 (1 hour and 24 hours) after start of infusion.

ECG Measurements: QTcF (QT Interval (interval from the beginning of the QRS complex to the end of the T wave) changes from baseline at each time point: The QTcF post baseline measurement obtained at time t minus baseline QTcF measurement. The 350 mg + LDAC arm of phase I and II were combined into one arm to provide maximum information on QT changes and presented together with the Phase I schedule B 450 mg arm, as pre specified in the study protocol.

Outcome measures

Outcome measures
Measure	Phase I Schedule A. Volasertib+LDAC n=50 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and LDAC 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle until the patient met criteria for stopping study medication during the MTD evaluation period.	Phase I Schedule B. Volasertib n=23 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) until the patient met criteria for stopping study medication during the MTD evaluation period	Phase I Schedule A. Volasertib 250 mg+LDAC Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 300 mg+LDAC Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 400 mg+LDAC Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Total Phase I Combined. Schedule A. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps up to 400 mg, with a starting dose of 400 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes and LDAC 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule B. Volasertib 150 mg Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 200 mg Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 350 mg Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 400 mg Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 450 mg Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 500 mg Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 550 mg Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Total Phase I Combined. Schedule B. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps from an initial starting dose of 150 mg. Dose was escalated up to 550 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes.	Phase II Schedule C. LDAC Low-dose cytarabine (LDAC) monotherapy 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Phase II Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) on Days 1 and 15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Total Phase II Combined. Schedule A and C. Volasertib escalating dose on Days 1 and 15 (28-day cycle). Dose escalation in 50 milligram (mg) steps up to 400 mg, with a starting dose of 150 mg. Volasertib 350 mg on Days 1+15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
QTcF (QT Interval Corrected for Heart Rate Using Fridericia's Formula) Change From Baseline at Cycle 1 Change from baseline after 1 hour	18.5 millisecond (ms) Standard Deviation 10.4	29.6 millisecond (ms) Standard Deviation 8.1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
QTcF (QT Interval Corrected for Heart Rate Using Fridericia's Formula) Change From Baseline at Cycle 1 Change from baseline after 24 hour	1.9 millisecond (ms) Standard Deviation 10.5	-0.5 millisecond (ms) Standard Deviation 9.8	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: First treatment cycle, up to 28 days.

Population: Treated set-Phase I part: Treated set was defined as all patients in Phase I who received at least a single dose of either Volasertib or LDAC, including patients who were replaced for any reason.

Number of patients with AEs following in the categories 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related AE) of CTCAE is reported.

Outcome measures

Outcome measures
Measure	Phase I Schedule A. Volasertib+LDAC n=4 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and LDAC 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle until the patient met criteria for stopping study medication during the MTD evaluation period.	Phase I Schedule B. Volasertib n=3 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) until the patient met criteria for stopping study medication during the MTD evaluation period	Phase I Schedule A. Volasertib 250 mg+LDAC n=5 Participants Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 300 mg+LDAC n=9 Participants Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 350 mg+LDAC n=8 Participants Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 400 mg+LDAC n=3 Participants Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Total Phase I Combined. Schedule A. n=32 Participants Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps up to 400 mg, with a starting dose of 400 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes and LDAC 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule B. Volasertib 150 mg Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 200 mg Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 350 mg Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 400 mg Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 450 mg Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 500 mg Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 550 mg Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Total Phase I Combined. Schedule B. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps from an initial starting dose of 150 mg. Dose was escalated up to 550 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes.	Phase II Schedule C. LDAC Low-dose cytarabine (LDAC) monotherapy 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Phase II Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) on Days 1 and 15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Total Phase II Combined. Schedule A and C. Volasertib escalating dose on Days 1 and 15 (28-day cycle). Dose escalation in 50 milligram (mg) steps up to 400 mg, with a starting dose of 150 mg. Volasertib 350 mg on Days 1+15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Phase I Schedule A: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During Cycle 1 Grade 3	0 Participants	0 Participants	1 Participants	1 Participants	2 Participants	1 Participants	5 Participants	—	—	—	—	—	—	—	—	—	—	—
Phase I Schedule A: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During Cycle 1 Grade 4	2 Participants	3 Participants	3 Participants	5 Participants	3 Participants	1 Participants	17 Participants	—	—	—	—	—	—	—	—	—	—	—
Phase I Schedule A: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During Cycle 1 Grade 5	0 Participants	0 Participants	0 Participants	3 Participants	2 Participants	1 Participants	6 Participants	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: First treatment cycle, up to 28 days.

Number of patients with AEs following in the categories 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related AE) of CTCAE is reported.

Outcome measures

Outcome measures
Measure	Phase I Schedule A. Volasertib+LDAC n=11 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and LDAC 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle until the patient met criteria for stopping study medication during the MTD evaluation period.	Phase I Schedule B. Volasertib n=2 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) until the patient met criteria for stopping study medication during the MTD evaluation period	Phase I Schedule A. Volasertib 250 mg+LDAC n=5 Participants Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 300 mg+LDAC n=6 Participants Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 350 mg+LDAC n=23 Participants Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 400 mg+LDAC n=5 Participants Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Total Phase I Combined. Schedule A. n=4 Participants Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps up to 400 mg, with a starting dose of 400 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes and LDAC 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule B. Volasertib 150 mg n=56 Participants Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 200 mg Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 350 mg Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 400 mg Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 450 mg Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 500 mg Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 550 mg Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Total Phase I Combined. Schedule B. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps from an initial starting dose of 150 mg. Dose was escalated up to 550 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes.	Phase II Schedule C. LDAC Low-dose cytarabine (LDAC) monotherapy 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Phase II Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) on Days 1 and 15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Total Phase II Combined. Schedule A and C. Volasertib escalating dose on Days 1 and 15 (28-day cycle). Dose escalation in 50 milligram (mg) steps up to 400 mg, with a starting dose of 150 mg. Volasertib 350 mg on Days 1+15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Phase I Schedule B: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During Cycle 1 Grade 3	5 Participants	0 Participants	1 Participants	0 Participants	5 Participants	0 Participants	0 Participants	11 Participants	—	—	—	—	—	—	—	—	—	—
Phase I Schedule B: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During Cycle 1 Grade 4	4 Participants	1 Participants	3 Participants	4 Participants	14 Participants	1 Participants	3 Participants	30 Participants	—	—	—	—	—	—	—	—	—	—
Phase I Schedule B: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During Cycle 1 Grade 5	1 Participants	1 Participants	0 Participants	0 Participants	2 Participants	1 Participants	1 Participants	6 Participants	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 615 days.

Number of patients with AEs following in the categories 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related AE) of CTCAE is reported.

Outcome measures

Outcome measures
Measure	Phase I Schedule A. Volasertib+LDAC n=4 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and LDAC 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle until the patient met criteria for stopping study medication during the MTD evaluation period.	Phase I Schedule B. Volasertib n=3 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) until the patient met criteria for stopping study medication during the MTD evaluation period	Phase I Schedule A. Volasertib 250 mg+LDAC n=5 Participants Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 300 mg+LDAC n=9 Participants Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 350 mg+LDAC n=8 Participants Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 400 mg+LDAC n=3 Participants Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Total Phase I Combined. Schedule A. n=32 Participants Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps up to 400 mg, with a starting dose of 400 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes and LDAC 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule B. Volasertib 150 mg Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 200 mg Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 350 mg Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 400 mg Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 450 mg Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 500 mg Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 550 mg Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Total Phase I Combined. Schedule B. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps from an initial starting dose of 150 mg. Dose was escalated up to 550 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes.	Phase II Schedule C. LDAC Low-dose cytarabine (LDAC) monotherapy 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Phase II Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) on Days 1 and 15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Total Phase II Combined. Schedule A and C. Volasertib escalating dose on Days 1 and 15 (28-day cycle). Dose escalation in 50 milligram (mg) steps up to 400 mg, with a starting dose of 150 mg. Volasertib 350 mg on Days 1+15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Phase I Schedule A: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During All Cycles Grade 3	1 Participants	0 Participants	0 Participants	1 Participants	2 Participants	1 Participants	5 Participants	—	—	—	—	—	—	—	—	—	—	—
Phase I Schedule A: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During All Cycles Grade 4	1 Participants	3 Participants	5 Participants	5 Participants	3 Participants	1 Participants	18 Participants	—	—	—	—	—	—	—	—	—	—	—
Phase I Schedule A: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During All Cycles Grade 5	1 Participants	0 Participants	0 Participants	3 Participants	2 Participants	1 Participants	7 Participants	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 597 days.

Population: Treated set-Phase I part: the treated set was defined as all patients in Phase I who received at least a single dose of either Volasertib or LDAC, including patients who were replaced for any reason.

Number of patients with AEs following in the categories 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related AE) of CTCAE is reported.

Outcome measures

Outcome measures
Measure	Phase I Schedule A. Volasertib+LDAC n=11 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and LDAC 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle until the patient met criteria for stopping study medication during the MTD evaluation period.	Phase I Schedule B. Volasertib n=2 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) until the patient met criteria for stopping study medication during the MTD evaluation period	Phase I Schedule A. Volasertib 250 mg+LDAC n=5 Participants Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 300 mg+LDAC n=6 Participants Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 350 mg+LDAC n=23 Participants Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 400 mg+LDAC n=5 Participants Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Total Phase I Combined. Schedule A. n=4 Participants Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps up to 400 mg, with a starting dose of 400 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes and LDAC 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule B. Volasertib 150 mg n=56 Participants Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 200 mg Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 350 mg Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 400 mg Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 450 mg Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 500 mg Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 550 mg Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Total Phase I Combined. Schedule B. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps from an initial starting dose of 150 mg. Dose was escalated up to 550 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes.	Phase II Schedule C. LDAC Low-dose cytarabine (LDAC) monotherapy 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Phase II Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) on Days 1 and 15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Total Phase II Combined. Schedule A and C. Volasertib escalating dose on Days 1 and 15 (28-day cycle). Dose escalation in 50 milligram (mg) steps up to 400 mg, with a starting dose of 150 mg. Volasertib 350 mg on Days 1+15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Phase I Schedule B: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During All Cycles Grade 3	5 Participants	0 Participants	1 Participants	0 Participants	3 Participants	0 Participants	0 Participants	9 Participants	—	—	—	—	—	—	—	—	—	—
Phase I Schedule B: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During All Cycles Grade 4	4 Participants	1 Participants	3 Participants	5 Participants	15 Participants	1 Participants	3 Participants	32 Participants	—	—	—	—	—	—	—	—	—	—
Phase I Schedule B: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During All Cycles Grade 5	2 Participants	1 Participants	0 Participants	0 Participants	3 Participants	2 Participants	1 Participants	9 Participants	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 890 days.

Population: Treated set-Phase II part: the treated set (Phase II) was defined as all patients in Phase II who received at least a single dose of either Volasertib or LDAC.

Number of patients with AEs following in the in the categories 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related AE) of CTCAE is reported.

Outcome measures

Outcome measures
Measure	Phase I Schedule A. Volasertib+LDAC n=45 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and LDAC 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle until the patient met criteria for stopping study medication during the MTD evaluation period.	Phase I Schedule B. Volasertib n=42 Participants Patients were treated in the dose-escalation phase with Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) until the patient met criteria for stopping study medication during the MTD evaluation period	Phase I Schedule A. Volasertib 250 mg+LDAC Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 300 mg+LDAC Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 400 mg+LDAC Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Total Phase I Combined. Schedule A. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps up to 400 mg, with a starting dose of 400 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes and LDAC 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule B. Volasertib 150 mg Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 200 mg Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 350 mg Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 400 mg Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 450 mg Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 500 mg Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 550 mg Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Total Phase I Combined. Schedule B. Volasertib escalating dose on Days 1+15 (28-day cycle). Dose escalation in 50 mg steps from an initial starting dose of 150 mg. Dose was escalated up to 550 mg. Volasertib administered by Intravenous Infusion (IV) over 60 minutes.	Phase II Schedule C. LDAC Low-dose cytarabine (LDAC) monotherapy 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Phase II Schedule A. Volasertib 350 mg+LDAC Volasertib 350 milligram (mg) on Days 1 and 15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Total Phase II Combined. Schedule A and C. Volasertib escalating dose on Days 1 and 15 (28-day cycle). Dose escalation in 50 milligram (mg) steps up to 400 mg, with a starting dose of 150 mg. Volasertib 350 mg on Days 1+15 (28-day cycle) administered by Intravenous Infusion (IV) over 60 minutes and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Phase II: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During All Cycles Grade 4	13 Participants	20 Participants	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Phase II: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During All Cycles Grade 5	6 Participants	8 Participants	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Phase II: Number of Participants With Adverse Events (AEs) Graded According to Common Terminology Criteria for Adverse Events (CTCAE), Based on the Number of Patients With AEs With CTCAE Grade ≥3 During All Cycles Grade 3	13 Participants	12 Participants	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

Adverse Events

Phase II Schedule C. LDAC

Serious events: 29 serious events

Other events: 43 other events

Deaths: 45 deaths

Phase I Schedule A. Volasertib 150 mg+LDAC

Serious events: 2 serious events

Other events: 4 other events

Deaths: 4 deaths

Phase I Schedule A. Volasertib 200 mg+LDAC

Serious events: 3 serious events

Other events: 3 other events

Deaths: 3 deaths

Phase I Schedule A. Volasertib 250 mg+LDAC

Serious events: 3 serious events

Other events: 5 other events

Deaths: 4 deaths

Phase I Schedule A. Volasertib 300 mg+LDAC

Serious events: 7 serious events

Other events: 9 other events

Deaths: 9 deaths

Phase I Schedule A. Volasertib 350 mg+LDAC

Serious events: 6 serious events

Other events: 8 other events

Deaths: 8 deaths

Phase II Schedule A. Volasertib 350 mg+LDAC

Serious events: 34 serious events

Other events: 41 other events

Deaths: 38 deaths

Phase I Schedule A. Volasertib 400 mg+LDAC

Serious events: 3 serious events

Other events: 3 other events

Deaths: 3 deaths

Phase I Schedule B. Volasertib 150 mg

Serious events: 7 serious events

Other events: 11 other events

Deaths: 11 deaths

Phase I Schedule B. Volasertib 200 mg

Serious events: 1 serious events

Other events: 2 other events

Deaths: 2 deaths

Phase I Schedule B. Volasertib 350 mg

Serious events: 3 serious events

Other events: 5 other events

Deaths: 3 deaths

Phase I Schedule B. Volasertib 400 mg

Serious events: 3 serious events

Other events: 6 other events

Deaths: 6 deaths

Phase I Schedule B. Volasertib 450 mg

Serious events: 16 serious events

Other events: 23 other events

Deaths: 21 deaths

Phase I Schedule B. Volasertib 500 mg

Serious events: 3 serious events

Other events: 5 other events

Deaths: 5 deaths

Phase I Schedule B. Volasertib 550 mg

Serious events: 3 serious events

Other events: 4 other events

Deaths: 4 deaths

Serious adverse events

Serious adverse events
Measure	Phase II Schedule C. LDAC n=45 participants at risk Low-dose cytarabine (LDAC) monotherapy 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Phase I Schedule A. Volasertib 150 mg+LDAC n=4 participants at risk Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 200 mg+LDAC n=3 participants at risk Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 250 mg+LDAC n=5 participants at risk Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 300 mg+LDAC n=9 participants at risk Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 350 mg+LDAC n=8 participants at risk Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase II Schedule A. Volasertib 350 mg+LDAC n=42 participants at risk Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 400 mg+LDAC n=3 participants at risk Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule B. Volasertib 150 mg n=11 participants at risk Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 200 mg n=2 participants at risk Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 350 mg n=5 participants at risk Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 400 mg n=6 participants at risk Phase I Schedule B. Volasertib 400 mg Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 450 mg n=23 participants at risk Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 500 mg n=5 participants at risk Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 550 mg n=4 participants at risk Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
Blood and lymphatic system disorders Anaemia	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.9% 5/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Blood and lymphatic system disorders Bone marrow failure	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Blood and lymphatic system disorders Febrile bone marrow aplasia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Blood and lymphatic system disorders Febrile neutropenia	13.3% 6/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 2/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	66.7% 2/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	22.2% 2/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	37.5% 3/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	54.8% 23/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	66.7% 2/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 2/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	39.1% 9/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Blood and lymphatic system disorders Leukocytosis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Blood and lymphatic system disorders Lymphadenopathy	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Blood and lymphatic system disorders Neutropenia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Blood and lymphatic system disorders Pancytopenia	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Blood and lymphatic system disorders Thrombocytopenia	4.4% 2/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.9% 5/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Acute coronary syndrome	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Acute myocardial infarction	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Angina pectoris	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Angina unstable	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Arrhythmia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Cardiac failure	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Cardiac failure congestive	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Long QT syndrome	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Myocardial infarction	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Myocardial ischaemia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Ventricular fibrillation	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Ear and labyrinth disorders Vertigo	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Abdominal pain	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Anal haemorrhage	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Constipation	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Diarrhoea	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 1/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Diarrhoea haemorrhagic	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Gastrointestinal disorder	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Gastrointestinal haemorrhage	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Haemorrhoids	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Ileus	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Mouth ulceration	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Tongue haematoma	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Upper gastrointestinal haemorrhage	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Vomiting	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Asthenia	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Chest pain	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders General physical health deterioration	11.1% 5/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	22.2% 2/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Hypothermia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Mucosal haemorrhage	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Mucosal inflammation	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 2/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Pain	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Pyrexia	17.8% 8/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.9% 5/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Hepatobiliary disorders Hepatic failure	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Immune system disorders Hypersensitivity	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Abscess	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Abscess neck	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Arthritis bacterial	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Aspergillus infection	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Bacterial pyelonephritis	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Bronchitis	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Cellulitis	4.4% 2/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Cerebral fungal infection	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Clostridium difficile infection	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Cystitis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Device related infection	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Endocarditis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Erysipelas	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Escherichia sepsis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Gastroenteritis norovirus	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Herpes zoster	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Infection	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Lung infection	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Neutropenic sepsis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Pneumonia	4.4% 2/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	19.0% 8/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	27.3% 3/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	17.4% 4/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Pneumonia fungal	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 2/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Pseudomembranous colitis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Pseudomonal sepsis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Pulmonary mycosis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Respiratory syncytial virus infection	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Sepsis	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	7.1% 3/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Soft tissue infection	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Staphylococcal infection	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Stenotrophomonas infection	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Tonsillitis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Urinary tract infection	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Urosepsis	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Injury, poisoning and procedural complications Meniscus injury	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Injury, poisoning and procedural complications Subdural haematoma	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Brain natriuretic peptide increased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations C-reactive protein increased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	60.0% 3/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Oxygen saturation decreased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Metabolism and nutrition disorders Dehydration	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Metabolism and nutrition disorders Hypoalbuminaemia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Musculoskeletal and connective tissue disorders Back pain	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Musculoskeletal and connective tissue disorders Bone pain	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Musculoskeletal and connective tissue disorders Crystal arthropathy	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Musculoskeletal and connective tissue disorders Muscular weakness	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Musculoskeletal and connective tissue disorders Osteoarthritis	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Musculoskeletal and connective tissue disorders Polyarthritis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Acute myeloid leukaemia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant neoplasm progression	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 1/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neoplasm malignant	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Nervous system disorders Cerebral haemorrhage	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Nervous system disorders Dizziness	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Nervous system disorders Headache	4.4% 2/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Nervous system disorders Hypoaesthesia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Nervous system disorders Neuralgia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Nervous system disorders Somnolence	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Nervous system disorders Syncope	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Psychiatric disorders Acute psychosis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Psychiatric disorders Confusional state	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Psychiatric disorders Depression	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Renal and urinary disorders Dysuria	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Renal and urinary disorders Nephropathy	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Renal and urinary disorders Renal failure	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Renal and urinary disorders Urinary retention	4.4% 2/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Dyspnoea	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Interstitial lung disease	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Hyperventilation	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Lung infiltration	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Pulmonary oedema	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Respiratory distress	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Skin and subcutaneous tissue disorders Dermatitis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Skin and subcutaneous tissue disorders Dermatitis allergic	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Surgical and medical procedures Catheterisation venous	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Vascular disorders Circulatory collapse	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Vascular disorders Deep vein thrombosis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Vascular disorders Haemorrhage	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Vascular disorders Hypotension	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Gastritis erosive	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Nausea	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Multiple organ dysfunction syndrome	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Oedema peripheral	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Klebsiella sepsis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Central nervous system leukaemia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Nervous system disorders Seizure	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.

Other adverse events

Other adverse events
Measure	Phase II Schedule C. LDAC n=45 participants at risk Low-dose cytarabine (LDAC) monotherapy 2x20 milligram (mg) per day administered by subcutaneous injection on days 1-10 of each 28 days treatment cycle.	Phase I Schedule A. Volasertib 150 mg+LDAC n=4 participants at risk Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 200 mg+LDAC n=3 participants at risk Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 250 mg+LDAC n=5 participants at risk Volasertib 250 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 300 mg+LDAC n=9 participants at risk Volasertib 300 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 350 mg+LDAC n=8 participants at risk Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase II Schedule A. Volasertib 350 mg+LDAC n=42 participants at risk Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule A. Volasertib 400 mg+LDAC n=3 participants at risk Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle) and Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.	Phase I Schedule B. Volasertib 150 mg n=11 participants at risk Volasertib 150 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 200 mg n=2 participants at risk Volasertib 200 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 350 mg n=5 participants at risk Volasertib 350 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 400 mg n=6 participants at risk Phase I Schedule B. Volasertib 400 mg Volasertib 400 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 450 mg n=23 participants at risk Volasertib 450 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 500 mg n=5 participants at risk Volasertib 500 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).	Phase I Schedule B. Volasertib 550 mg n=4 participants at risk Volasertib 550 milligram (mg) administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
Gastrointestinal disorders Proctalgia	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Rectal haemorrhage	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Small intestine ulcer	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Stomatitis	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	21.7% 5/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	60.0% 3/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Tongue coated	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Tongue ulceration	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Toothache	4.4% 2/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Vomiting	13.3% 6/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 2/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	44.4% 4/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	38.1% 16/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 1/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	26.1% 6/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Adverse drug reaction	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Blood and lymphatic system disorders Leukocytosis	6.7% 3/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	36.4% 4/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Angina pectoris	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Blood and lymphatic system disorders Anaemia	26.7% 12/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	66.7% 2/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	80.0% 4/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	66.7% 6/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	37.5% 3/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 14/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	36.4% 4/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	100.0% 2/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	100.0% 5/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	66.7% 4/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	47.8% 11/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 2/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Blood and lymphatic system disorders Febrile neutropenia	8.9% 4/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	19.0% 8/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	17.4% 4/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Blood and lymphatic system disorders Leukopenia	6.7% 3/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	55.6% 5/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	18.2% 2/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 1/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 2/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	30.4% 7/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Blood and lymphatic system disorders Lymphadenopathy	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 1/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Blood and lymphatic system disorders Neutropenia	11.1% 5/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	66.7% 2/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	26.2% 11/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	18.2% 2/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 1/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 3/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	52.2% 12/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Blood and lymphatic system disorders Splenomegaly	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	22.2% 2/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 1/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Eye disorders Macular degeneration	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Blood and lymphatic system disorders Thrombocytopenia	17.8% 8/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	66.7% 2/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	80.0% 4/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	55.6% 5/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	37.5% 3/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	21.4% 9/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	45.5% 5/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 1/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	60.0% 3/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 2/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	52.2% 12/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 2/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Aortic valve incompetence	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Arteriosclerosis coronary artery	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Atrioventricular block	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Bradycardia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Bundle branch block right	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	8.7% 2/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Cardiac arrest	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Cardiac disorder	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Cardiac failure	4.4% 2/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Cardiac valve disease	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Cardiomegaly	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Cardiomyopathy	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Cardiovascular disorder	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Congestive cardiomyopathy	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Extrasystoles	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Heart valve incompetence	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Hypertensive heart disease	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Left ventricular hypertrophy	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Mitral valve incompetence	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	18.2% 2/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Palpitations	8.9% 4/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Pericardial effusion	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	22.2% 2/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 2/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Tachyarrhythmia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Tachycardia	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Tricuspid valve incompetence	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	18.2% 2/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Ventricular extrasystoles	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Ear and labyrinth disorders Ear haemorrhage	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Ear and labyrinth disorders Vertigo	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	22.2% 2/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	7.1% 3/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	8.7% 2/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Endocrine disorders Adrenal disorder	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Eye disorders Cataract	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Eye disorders Dry eye	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Eye disorders Erythema of eyelid	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Eye disorders Eye haemorrhage	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	8.7% 2/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Eye disorders Eyelid oedema	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Eye disorders Glaucoma	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Eye disorders Lacrimation increased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Eye disorders Visual acuity reduced	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Eye disorders Visual impairment	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Abdominal pain	8.9% 4/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	22.2% 2/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.5% 4/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	17.4% 4/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Abdominal pain upper	8.9% 4/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	7.1% 3/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	8.7% 2/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Abnormal faeces	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Anal haemorrhage	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Oesophagitis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Ascites	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Constipation	26.7% 12/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	100.0% 3/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	22.2% 2/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	37.5% 3/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	42.9% 18/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	27.3% 3/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 1/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	26.1% 6/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 2/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Diarrhoea	24.4% 11/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 2/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	66.7% 2/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	44.4% 4/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	31.0% 13/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 3/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	26.1% 6/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Dry mouth	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	66.7% 2/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	22.2% 2/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Dyspepsia	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	7.1% 3/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Dysphagia	4.4% 2/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	66.7% 2/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	7.1% 3/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Enterocolitis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Faecaloma	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Flatulence	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 4/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Gastritis	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Gastrointestinal inflammation	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Gingival bleeding	4.4% 2/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Gingival discolouration	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Gingival pain	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Gingival swelling	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Glossodynia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Haematochezia	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Haemorrhoids	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Hiatus hernia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Mouth haemorrhage	6.7% 3/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	13.0% 3/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Mouth ulceration	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Nausea	35.6% 16/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 2/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	44.4% 4/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 4/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	45.2% 19/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	66.7% 2/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	18.2% 2/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	30.4% 7/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 2/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Oral mucosal erythema	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Oral pain	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	7.1% 3/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Periodontal disease	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Asthenia	24.4% 11/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	23.8% 10/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Calcinosis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Catheter site erythema	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Catheter site oedema	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Chest discomfort	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Chest pain	6.7% 3/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	22.2% 2/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.5% 4/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Chills	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	37.5% 3/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	66.7% 2/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Fatigue	24.4% 11/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	100.0% 5/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	55.6% 5/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 4/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	26.2% 11/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	27.3% 3/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	100.0% 2/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	17.4% 4/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 2/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Feeling cold	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Pyrexia	17.8% 8/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	44.4% 4/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	31.0% 13/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	8.7% 2/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Feeling hot	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Feeling of body temperature change	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Thirst decreased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Gait disturbance	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders General physical health deterioration	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	37.5% 3/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.9% 5/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 2/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	56.5% 13/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Granuloma	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Induration	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Inflammation	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	8.7% 2/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Influenza like illness	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Infusion site pain	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Injection site haematoma	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	7.1% 3/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Injection site reaction	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Local swelling	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Localised oedema	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Malaise	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Mucosal inflammation	4.4% 2/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	22.2% 2/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	37.5% 3/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	23.8% 10/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 2/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	8.7% 2/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Oedema	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	13.0% 3/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Oedema mucosal	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Device related infection	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Oedema peripheral	20.0% 9/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	66.7% 2/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	55.6% 5/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 2/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	28.6% 12/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	18.2% 2/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 1/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	39.1% 9/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Pain	6.7% 3/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	37.5% 3/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.9% 5/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	27.3% 3/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	13.0% 3/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Puncture site pain	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Hepatobiliary disorders Cholelithiasis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Hepatobiliary disorders Hepatic congestion	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Hepatobiliary disorders Hepatic cyst	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Hepatobiliary disorders Hepatic lesion	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Hepatobiliary disorders Hepatomegaly	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Hepatobiliary disorders Hyperbilirubinaemia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	13.0% 3/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Bacterial infection	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Beta haemolytic streptococcal infection	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Bronchitis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Candida infection	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Clostridium difficile infection	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Cystitis	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 1/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Diverticulitis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Enterococcal infection	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Erysipelas	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Escherichia bacteraemia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Injury, poisoning and procedural complications Wound	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Escherichia infection	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Fungal infection	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Fungal skin infection	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Fusobacterium infection	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Gingivitis	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Herpes simplex	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Herpes virus infection	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Herpes zoster	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Micrococcus infection	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Nail bed infection	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Nasopharyngitis	4.4% 2/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	44.4% 4/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 2/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Oral candidiasis	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Oral herpes	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	13.0% 3/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Pharyngitis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	13.0% 3/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Injury, poisoning and procedural complications Excoriation	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 1/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Pneumonia	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.9% 5/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	13.0% 3/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Pneumonia fungal	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Pseudomonas infection	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	8.7% 2/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Sepsis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Skin infection	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Staphylococcal infection	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Urinary tract infection	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	7.1% 3/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Urosepsis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Blood lactate dehydrogenase decreased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Injury, poisoning and procedural complications Allergic transfusion reaction	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Injury, poisoning and procedural complications Drug administration error	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Injury, poisoning and procedural complications Fall	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	44.4% 4/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.5% 4/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	17.4% 4/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Injury, poisoning and procedural complications Laceration	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Injury, poisoning and procedural complications Lip injury	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Injury, poisoning and procedural complications Procedural pain	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Injury, poisoning and procedural complications Transfusion reaction	4.4% 2/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	8.7% 2/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Activated partial thromboplastin time prolonged	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	13.0% 3/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Activated partial thromboplastin time shortened	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Alanine aminotransferase increased	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	100.0% 3/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	18.2% 2/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	17.4% 4/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Aspartate aminotransferase increased	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	66.7% 2/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 1/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	21.7% 5/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Blast cell count increased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Blood albumin decreased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Blood albumin increased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Blood alkaline phosphatase increased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	27.3% 3/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	8.7% 2/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Blood bilirubin increased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	66.7% 2/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	18.2% 2/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	8.7% 2/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Blood chloride increased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Blood creatine phosphokinase decreased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Blood creatine phosphokinase increased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Blood creatinine	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Blood creatinine decreased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	22.2% 2/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Blood creatinine increased	6.7% 3/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 3/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	18.2% 2/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 1/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 2/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	26.1% 6/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 2/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Blood fibrinogen increased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Blood glucose increased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Blood iron decreased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Blood iron increased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Blood lactate dehydrogenase increased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	36.4% 4/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	13.0% 3/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Blood phosphorus decreased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Blood potassium decreased	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 2/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Blood pressure increased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 2/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Blood triglycerides increased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Blood urea decreased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Blood urea increased	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	22.2% 2/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	27.3% 3/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 1/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 2/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Blood uric acid increased	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 1/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	8.7% 2/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Blood urine present	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Body temperature increased	4.4% 2/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Protein total decreased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	27.3% 3/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	8.7% 2/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Prothrombin time prolonged	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	8.7% 2/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Breath sounds abnormal	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations C-reactive protein increased	11.1% 5/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 2/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	44.4% 4/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 4/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	36.4% 4/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	100.0% 2/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 3/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	30.4% 7/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	75.0% 3/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Candida test positive	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Ejection fraction decreased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Electrocardiogram QT prolonged	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	21.7% 5/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Electrocardiogram change	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Enterococcus test positive	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Escherichia test positive	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Gamma-glutamyltransferase increased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	66.7% 2/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	36.4% 4/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	13.0% 3/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Heart rate increased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Hepatic enzyme increased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Liver function test abnormal	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Oxygen saturation decreased	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Prostatic specific antigen increased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Serum ferritin increased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Thrombin time shortened	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Troponin T increased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	13.0% 3/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Troponin increased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Weight decreased	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations Weight increased	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 1/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations White blood cells urine	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Metabolism and nutrition disorders Acidosis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Metabolism and nutrition disorders Alkalosis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Metabolism and nutrition disorders Decreased appetite	13.3% 6/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 2/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	66.7% 2/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	80.0% 4/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	55.6% 5/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 2/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	14.3% 6/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	27.3% 3/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 2/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	43.5% 10/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Metabolism and nutrition disorders Dehydration	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Metabolism and nutrition disorders Diabetes mellitus	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Metabolism and nutrition disorders Hypercholesterolaemia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Skin and subcutaneous tissue disorders Eczema	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Metabolism and nutrition disorders Hyperglycaemia	4.4% 2/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	66.7% 2/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	80.0% 4/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	100.0% 2/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	7.1% 3/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Metabolism and nutrition disorders Hypernatraemia	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Metabolism and nutrition disorders Hyperuricaemia	8.9% 4/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	22.2% 2/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	18.2% 2/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	13.0% 3/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Metabolism and nutrition disorders Hypoalbuminaemia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	17.4% 4/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Metabolism and nutrition disorders Hypocalcaemia	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	60.0% 3/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	22.2% 2/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	18.2% 2/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	100.0% 2/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	26.1% 6/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Metabolism and nutrition disorders Hypoglycaemia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Metabolism and nutrition disorders Hypokalaemia	6.7% 3/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	80.0% 4/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	44.4% 4/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	75.0% 6/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	19.0% 8/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	100.0% 3/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	18.2% 2/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	43.5% 10/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 2/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	60.0% 3/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	44.4% 4/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 1/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	8.7% 2/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Metabolism and nutrition disorders Hypoproteinaemia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	8.7% 2/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Metabolism and nutrition disorders Iron overload	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Metabolism and nutrition disorders Uraemic acidosis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 1/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Metabolism and nutrition disorders Vitamin D deficiency	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Musculoskeletal and connective tissue disorders Arthralgia	8.9% 4/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 3/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 7/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	13.0% 3/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	60.0% 3/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Musculoskeletal and connective tissue disorders Arthritis	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Musculoskeletal and connective tissue disorders Back pain	22.2% 10/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 2/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	22.2% 2/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	14.3% 6/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	13.0% 3/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Musculoskeletal and connective tissue disorders Bone lesion	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Musculoskeletal and connective tissue disorders Bone pain	4.4% 2/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Musculoskeletal and connective tissue disorders Flank pain	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Musculoskeletal and connective tissue disorders Groin pain	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Musculoskeletal and connective tissue disorders Joint swelling	4.4% 2/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Musculoskeletal and connective tissue disorders Muscle spasms	6.7% 3/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Musculoskeletal and connective tissue disorders Muscular weakness	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	13.0% 3/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	4.4% 2/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	66.7% 2/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Musculoskeletal and connective tissue disorders Myalgia	4.4% 2/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	7.1% 3/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Musculoskeletal and connective tissue disorders Myopathy	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Musculoskeletal and connective tissue disorders Osteoarthritis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Musculoskeletal and connective tissue disorders Osteolysis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Musculoskeletal and connective tissue disorders Osteopenia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Musculoskeletal and connective tissue disorders Osteoporosis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Musculoskeletal and connective tissue disorders Pain in extremity	13.3% 6/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 3/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	7.1% 3/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	13.0% 3/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Musculoskeletal and connective tissue disorders Spinal osteoarthritis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Chloroma	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	22.2% 2/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Leukaemia cutis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Meningioma	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neoplasm progression	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Small intestine carcinoma	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Nervous system disorders Burning sensation	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Nervous system disorders Dizziness	4.4% 2/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	80.0% 4/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	22.2% 2/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 2/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	7.1% 3/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	17.4% 4/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Nervous system disorders Headache	15.6% 7/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.5% 4/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	21.7% 5/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Nervous system disorders Hemiparesis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Nervous system disorders Orthostatic intolerance	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Nervous system disorders Paraesthesia	6.7% 3/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Nervous system disorders Peripheral sensory neuropathy	4.4% 2/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Nervous system disorders Polyneuropathy	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Nervous system disorders Sinus headache	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Nervous system disorders Somnolence	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Nervous system disorders Syncope	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Nervous system disorders Tremor	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 2/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Psychiatric disorders Agitation	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 2/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Psychiatric disorders Anxiety	4.4% 2/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.9% 5/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Psychiatric disorders Communication disorder	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Psychiatric disorders Confusional state	4.4% 2/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	8.7% 2/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Psychiatric disorders Depressed mood	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Psychiatric disorders Depression	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Psychiatric disorders Disorientation	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Psychiatric disorders Hallucination	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Psychiatric disorders Hallucination, visual	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Psychiatric disorders Initial insomnia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Psychiatric disorders Insomnia	8.9% 4/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	7.1% 3/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Psychiatric disorders Panic attack	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Psychiatric disorders Restlessness	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Psychiatric disorders Sleep disorder	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	7.1% 3/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	18.2% 2/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Psychiatric disorders Suicidal ideation	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Renal and urinary disorders Anuria	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 1/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Renal and urinary disorders Bladder pain	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Renal and urinary disorders Dysuria	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	7.1% 3/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	13.0% 3/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Renal and urinary disorders Haematuria	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	66.7% 2/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	22.2% 2/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Renal and urinary disorders Glycosuria	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Renal and urinary disorders Leukocyturia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Renal and urinary disorders Micturition disorder	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Renal and urinary disorders Nephropathy	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Renal and urinary disorders Nocturia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Renal and urinary disorders Pollakiuria	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Renal and urinary disorders Proteinuria	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Renal and urinary disorders Renal atrophy	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Renal and urinary disorders Renal cyst	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Renal and urinary disorders Renal impairment	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Renal and urinary disorders Renal pain	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Renal and urinary disorders Urethral haemorrhage	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 1/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Renal and urinary disorders Urethral pain	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Renal and urinary disorders Urinary incontinence	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	8.7% 2/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Renal and urinary disorders Urinary retention	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Reproductive system and breast disorders Breast enlargement	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Reproductive system and breast disorders Genital swelling	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Reproductive system and breast disorders Haematospermia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Reproductive system and breast disorders Nipple disorder	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Skin and subcutaneous tissue disorders Skin erosion	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Reproductive system and breast disorders Pelvic pain	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Reproductive system and breast disorders Penile oedema	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Reproductive system and breast disorders Scrotal oedema	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Reproductive system and breast disorders Vaginal haemorrhage	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Reproductive system and breast disorders Vulvovaginal erythema	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Atelectasis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Bronchial secretion retention	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Cough	13.3% 6/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	44.4% 4/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 2/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	23.8% 10/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	18.2% 2/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	26.1% 6/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Dysphonia	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Dyspnoea	17.8% 8/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	44.4% 4/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 2/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	23.8% 10/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 2/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	17.4% 4/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	60.0% 3/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	22.2% 2/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Epistaxis	20.0% 9/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 3/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 2/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	38.1% 16/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	18.2% 2/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 1/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 2/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	21.7% 5/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Haemoptysis	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.9% 5/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Hiccups	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Laryngeal disorder	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Lung disorder	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Lung infiltration	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	22.2% 2/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Nasal inflammation	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	4.4% 2/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.9% 5/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	13.0% 3/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Pharyngeal inflammation	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	8.7% 2/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Pleural effusion	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	44.4% 4/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	7.1% 3/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	18.2% 2/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	8.7% 2/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Productive cough	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Pulmonary hypertension	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Respiratory failure	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Sputum discoloured	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Sputum retention	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 1/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Vocal cord disorder	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Skin and subcutaneous tissue disorders Alopecia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 2/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	7.1% 3/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 3/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	13.0% 3/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 2/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Skin and subcutaneous tissue disorders Blister	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Skin and subcutaneous tissue disorders Blood blister	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	100.0% 2/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Skin and subcutaneous tissue disorders Dermatitis atopic	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Skin and subcutaneous tissue disorders Dermatitis exfoliative	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Skin and subcutaneous tissue disorders Dry skin	6.7% 3/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 3/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Skin and subcutaneous tissue disorders Erythema	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Skin and subcutaneous tissue disorders Haemorrhage subcutaneous	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 1/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Skin and subcutaneous tissue disorders Hyperhidrosis	4.4% 2/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	7.1% 3/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	18.2% 2/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Skin and subcutaneous tissue disorders Night sweats	6.7% 3/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.5% 4/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 3/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	13.0% 3/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Skin and subcutaneous tissue disorders Pain of skin	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Skin and subcutaneous tissue disorders Parapsoriasis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Skin and subcutaneous tissue disorders Petechiae	11.1% 5/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	22.2% 2/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 2/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	23.8% 10/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	66.7% 2/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	36.4% 4/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	66.7% 4/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	13.0% 3/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Skin and subcutaneous tissue disorders Pruritus	15.6% 7/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.5% 4/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	8.7% 2/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Skin and subcutaneous tissue disorders Psoriasis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Skin and subcutaneous tissue disorders Purpura	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	7.1% 3/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Skin and subcutaneous tissue disorders Rash	8.9% 4/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	7.1% 3/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	18.2% 2/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 1/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 3/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	17.4% 4/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Skin and subcutaneous tissue disorders Skin haemorrhage	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Skin and subcutaneous tissue disorders Skin hyperpigmentation	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Skin and subcutaneous tissue disorders Skin lesion	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Skin and subcutaneous tissue disorders Swelling face	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Skin and subcutaneous tissue disorders Urticaria	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Social circumstances Fasting	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Surgical and medical procedures Central venous catheterisation	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Surgical and medical procedures Nail operation	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Vascular disorders Angiopathy	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Vascular disorders Circulatory collapse	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Vascular disorders Haematoma	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	37.5% 3/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	18.2% 2/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 1/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 3/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	13.0% 3/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	40.0% 2/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Vascular disorders Haemorrhage	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Vascular disorders Hypertension	8.9% 4/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	21.7% 5/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	50.0% 2/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Vascular disorders Hypertensive crisis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 1/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Vascular disorders Hypotension	4.4% 2/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 7/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Vascular disorders Infarction	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Vascular disorders Peripheral coldness	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Vascular disorders Peripheral embolism	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Vascular disorders Thrombophlebitis	8.9% 4/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	16.7% 1/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	8.7% 2/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Vascular disorders Varicose vein	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	9.1% 1/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Blood and lymphatic system disorders Cytopenia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 2/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Anal incontinence	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 2/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Aphthous ulcer	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	7.1% 3/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Tongue discolouration	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Peripheral swelling	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	20.0% 1/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	22.2% 2/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.8% 2/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	33.3% 1/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Injury, poisoning and procedural complications Skin abrasion	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	11.1% 1/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Arrhythmia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Cardiac disorders Atrial fibrillation	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Eye disorders Hyphaema	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Eye disorders Photopsia	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Abdominal discomfort	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Gastric ulcer	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Gastrointestinal disorder	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Palatal disorder	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Gastrointestinal disorders Tongue haemorrhage	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Catheter site pain	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Discomfort	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Hyperthermia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
General disorders Mucosal haemorrhage	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Hepatobiliary disorders Hepatic steatosis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Osteomyelitis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Post procedural infection	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Infections and infestations Soft tissue infection	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Injury, poisoning and procedural complications Stoma site haemorrhage	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Investigations International normalised ratio increased	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Metabolism and nutrition disorders Fluid overload	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Nervous system disorders Ageusia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Nervous system disorders Dysgeusia	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Nervous system disorders Hypotonia	2.2% 1/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	25.0% 2/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	4.3% 1/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Renal and urinary disorders Chronic kidney disease	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Renal and urinary disorders Incontinence	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Renal and urinary disorders Micturition urgency	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Reproductive system and breast disorders Genital burning sensation	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Rales	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Rhonchi	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Respiratory, thoracic and mediastinal disorders Throat irritation	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Skin and subcutaneous tissue disorders Ingrowing nail	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Skin and subcutaneous tissue disorders Intertrigo	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Vascular disorders Lymphoedema	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.
Vascular disorders Phlebitis	0.00% 0/45 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/9 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	12.5% 1/8 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	2.4% 1/42 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/3 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/11 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/2 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/6 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/23 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/5 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.	0.00% 0/4 • From first drug administration until 21 days after the last trial drug administration in the last treatment cycle, up to 3325 days. Treated Set-phase I part: Treated Set was defined as all patients who received at least a single dose of either Volasertib or Low-dose cytarabine (LDAC), including patients who were replaced for any reason. Phase II part, the Treated Set was defined as all patients who received at least a single dose of either Volasertib or LDAC.

Additional Information

Boehringer Ingelheim, Call Center

Boehringer Ingelheim

Phone: 1800-243-0127

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.
Publication restrictions are in place

Restriction type: OTHER